Christopher Kiritsy
Direktor/Vorstandsmitglied bei PIERIS PHARMACEUTICALS, INC.
Vermögen: 2 900 $ am 30.04.2024
Aktive Positionen von Christopher Kiritsy
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PIERIS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 20.09.2016 | - |
Independent Dir/Board Member | 20.09.2016 | - | |
HTG MOLECULAR DIAGNOSTICS, INC. | Direktor/Vorstandsmitglied | 27.01.2022 | - |
Precision Kapital LLC | Gründer | 01.01.2018 | - |
Corporate Officer/Principal | 01.01.2018 | - |
Karriereverlauf von Christopher Kiritsy
Ehemalige bekannte Positionen von Christopher Kiritsy
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Arisaph Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Direktor/Vorstandsmitglied | 01.01.2005 | 01.01.2018 |
Vorstandsvorsitzender | 01.01.2005 | 01.01.2018 | |
Gründer | 01.01.1999 | 01.01.2018 | |
Präsident | 01.01.2005 | 01.01.2018 | |
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Finanzdirektor/CFO | - | 23.05.2005 |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Direktor/Vorstandsmitglied | 14.08.2014 | - |
University of Oregon | Corporate Officer/Principal | - | - |
Avaxia Biologics, Inc.
Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Vorsitzender | 26.04.2012 | - |
Ausbildung von Christopher Kiritsy
Boston University | Masters Business Admin |
Bowdoin College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 11 |
Operativ
Director/Board Member | 4 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
HTG MOLECULAR DIAGNOSTICS, INC. | Commercial Services |
PIERIS PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Health Technology |
Arisaph Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA | Health Technology |
Avaxia Biologics, Inc.
Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Health Technology |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
Precision Kapital LLC |
- Börse
- Insiders
- Christopher Kiritsy
- Erfahrung